These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27070091)

  • 21. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up.
    Mathis C; Lascombe I; Monnien F; Bittard H; Kleinclauss F; Bedgedjian I; Fauconnet S; Valmary-Degano S
    BMC Cancer; 2018 Dec; 18(1):1239. PubMed ID: 30526555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
    Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
    Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.
    Lin YL; Xie PG; Ma JG
    Med Sci Monit; 2014 Sep; 20():1572-7. PubMed ID: 25196672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of positive urine cytology on progression and cancer-specific mortality of non--muscle-invasive bladder cancer.
    Koga F; Kobayashi S; Fujii Y; Ishioka J; Yokoyama M; Nakanishi Y; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Clin Genitourin Cancer; 2014 Jun; 12(3):e87-93. PubMed ID: 24169493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
    Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
    Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
    Aziz A; Lessard A; Moore K; Hovington H; Latulippe E; Larue H; Fradet Y; Lacombe L
    BJU Int; 2011 Aug; 108(4):531-7. PubMed ID: 21166751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
    Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
    Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
    Poyet C; Buser L; Roudnicky F; Detmar M; Hermanns T; Mannhard D; Höhn A; Rüschoff J; Zhong Q; Sulser T; Moch H; Wild PJ
    J Clin Pathol; 2015 Oct; 68(10):819-24. PubMed ID: 26251520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.
    Wang L; Zhao J; Yang C; Kuang R; Kazobinka G; Pang Z; Hou T
    Cell Physiol Biochem; 2018; 48(6):2364-2373. PubMed ID: 30114689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
    Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
    Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Muscle-invasive bladder cancer is characterized by overexpression of thymidine kinase 1.
    Rausch S; Hennenlotter J; Teepe K; Kuehs U; Aufderklamm S; Bier S; Mischinger J; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2015 Oct; 33(10):426.e21-9. PubMed ID: 26231311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
    Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
    J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.